<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01620255</url>
  </required_header>
  <id_info>
    <org_study_id>A7281009</org_study_id>
    <secondary_id>2012-002030-37</secondary_id>
    <secondary_id>TURANDOT</secondary_id>
    <nct_id>NCT01620255</nct_id>
  </id_info>
  <brief_title>A Study Of PF-00547659 In Patients With Moderate To Severe Ulcerative Colitis</brief_title>
  <acronym>TURANDOT</acronym>
  <official_title>A Double-blind, Randomized, Placebo-controlled, Parallel, Dose-ranging Study To Evaluate The Efficacy And Safety Of Pf-00547659 In Subjects With Moderate To Severe Ulcerative Colitis (Turandot)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shire</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the dose or doses of PF-00547659 that will be the most effective to improve or
      halt the disease symptoms in patients with moderate to severe ulcerative colitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Clinical Remission at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical remission was defined as a Total Mayo Score of less than or equal (&lt;=) 2 points with no individual subscore exceeding 1 point and rectal bleed subscore of 0 or 1. The Mayo Score is a tool designed to measure disease activity for ulcerative colitis (UC). Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Clinical Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Clinical response was defined as a decrease from baseline of at least 3 points in Total Mayo Score with at least a 30 percent (%) change, accompanied by at least 1 point decrease or absolute score of 0 or 1 in rectal bleeding subscore. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Mucosal Healing at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Mucosal healing was defined as absolute Mayo subscore for endoscopy of 0 or 1. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Absolute Partial Mayo Score of Less Than or Equal to (&lt;=) 2 With no Individual Subscore More Than (&gt;) 1 at Weeks 4, 8, and 12</measure>
    <time_frame>Weeks 4, 8, and 12</time_frame>
    <description>An absolute Partial Mayo Score of &lt;=2 corresponds to remission. However, this endpoint was incorrectly stated in the protocol and instead of &quot;absolute Partial Mayo Score &lt;=2&quot;, it was stated as &quot;change from baseline in Partial Mayo Score &lt;=2&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Mayo Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change From Baseline in Individual Mayo Subscores - Stool Frequency, Rectal Bleeding, and Physician's Global Assessment (PGA) - at Weeks 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks (W) 4, 8, and 12</time_frame>
    <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of less than (&lt;) 0, 0, and &gt;0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Change From Baseline in Individual Mayo Subscore - Findings on Flexible Sigmoidoscopy - at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of &lt;0, 0, and &gt;0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in Fecal Calprotectin at Weeks 4, 8, and 12</measure>
    <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
    <description>Fecal calprotectin was one of the pharmacodynamic (PD) biomarkers of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 4, 8, and 12</measure>
    <time_frame>Baseline; Weeks 4, 8, and 12</time_frame>
    <description>hsCRP was one of the PD biomarkers of the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Scores at Week 12</measure>
    <time_frame>Baseline (BL), Week 12</time_frame>
    <description>IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. There are 4 individual domains under the IBDQ: bowel function (fx)/symptoms (score range of 10-70), systemic symptoms (score range of 5-35), emotional status/fx (score range of 12-84), and social fx (score range of 5-35). As with total score, higher scores indicate better QOL in that domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With an Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score of More Than or Equal to (&gt;=) 170 at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. A score of &gt;=170 corresponds to clinical remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs During the Treatment Period (Weeks 0-12)</measure>
    <time_frame>Screening through to end of treatment period, up to 12 weeks</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum PF-00547659 Concentration Achieved</measure>
    <time_frame>Weeks 0 (baseline), 2, 4,8, 12, 16, 20, 24, 28, 32, and 36; Early Withdrawal</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">357</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC Injection</intervention_name>
    <description>Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose Level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC Injection</intervention_name>
    <description>Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC Injection</intervention_name>
    <description>Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose Level 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-00547659 SC Injection</intervention_name>
    <description>Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks</description>
    <arm_group_label>Drug Dose Level 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with diagnosis of Ulcerative Colitis for 3 or more months.

          -  Ulcerative colitis must be active beyond the rectum.

          -  Must active Ulcerative Colitis with a Total Mayo Score of 6 to 12 points

        Exclusion Criteria:

          -  Pregnant or breast feeding.

          -  Diagnosis of indeterminate colitis or Crohn's Disease

          -  Subjects with history of colonic or small bowel obstruction or resection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Health System-Pharmacy only</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical and Translational Research Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perlman Medical Offices</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thornton Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Clinical Trials</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GastroDiagnostics - Community Clinical Trials Drug</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Clinical Research, LLC.</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research of the Rockies</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Gastroenterology Associates</name>
      <address>
        <city>Thornton</city>
        <state>Colorado</state>
        <zip>80229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopy Center of Connecticut, LLC</name>
      <address>
        <city>Guilford</city>
        <state>Connecticut</state>
        <zip>06437</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopy Center of Connecticut, LLC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Center of Connecticut, PC</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical REsearch Center of CT Drug</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research Network of Connecticut</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Surgery Center</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates</name>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <zip>34429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Consultant Group</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Th Palmetto Surgery Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Citrus Memorial Hospital</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inverness Medical Imaging</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nature Coast Clinical Research</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34452</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Endoscopy Center</name>
      <address>
        <city>Inverness</city>
        <state>Florida</state>
        <zip>34453</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sand Lake Imaging</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Diagnostic Imaging</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33179</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinic - Local Lab</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital and Clinic</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coral View Surgery Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Quality Laboratory</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FQL Research, LLC</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Venutre Ambulatory Sugery Center</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston Diagnostic Imaging</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Citrus Ambulatory Surgery Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Specialists</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shafran Gastroenterology Center</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgia Endoscopy Center</name>
      <address>
        <city>Alpharetta</city>
        <state>Georgia</state>
        <zip>30005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Consultants</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Gastroenterology Specialist</name>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <zip>30024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Central Laboratory Services Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Central Laboratory Services, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covance Laboratory Services, Inc</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46214</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Chandler Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky Medical Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoscopic Microsurgery Associates</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Commonwealth Clinical Studies</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Signature Healthcare Brockton</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health Systems</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Valley Endoscopy</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49546</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Associates of Western Michigan</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metro Health Endoscopy Unit</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Medical Eye Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Noran Neurology Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Heart Institute</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55441</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consulting Radiology</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Gastroenterology, P.A.</name>
      <address>
        <city>Plymouth</city>
        <state>Minnesota</state>
        <zip>55446</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Surgery Center of Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Digestive and Liver Diseases</name>
      <address>
        <city>Mexico</city>
        <state>Missouri</state>
        <zip>65265</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital Investigational Drug Service (IP Shipping Address)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes-Jewish Hospital Radiology (X-Ray Only)</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Advanced Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nevada School of Medicine (UNSOM)</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Steinberg Diagnostic Medical Imaging Centers</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Surgery Center</name>
      <address>
        <city>Nevada</city>
        <state>Nevada</state>
        <zip>89106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth-Hitchcock Medical Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>3756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital - Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College - New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College of Cornell University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley, PC</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group Research Department - Drug</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals Endoscopy Center At Meadowmont</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Pharmacy Investigational Drug Services</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Memorial Hospital</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Oregon Clinic, PC - Gastroenterology West</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro One</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Imaging</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center: GI Clinical Research</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212-1610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center: IBD Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center: Drug Shipment</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-7610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center: Endoscopy Lab</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center: Outpatient Radiology</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houston Hospital for Specialized Surgery</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Clinic (Drug Storage)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College Of Medicine - Baylor Medical Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology and Associates</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spring Gastroenterology Drug</name>
      <address>
        <city>Humble</city>
        <state>Texas</state>
        <zip>77338</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Digestive Disease Consultants</name>
      <address>
        <city>Southlake</city>
        <state>Texas</state>
        <zip>76092</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PI Radiology</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53222</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegiance Research Specialists</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dynacare Laboratories</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI associates drug</name>
      <address>
        <city>Wauwatosa</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Concord Repatriation General Hospital</name>
      <address>
        <city>Concord</city>
        <state>New South Wales</state>
        <zip>2139</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Health Services</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH Wien, Universitaetsklinik fuer Innere Medizin III</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ St-Elisabeth Herentals</name>
      <address>
        <city>Herentals</city>
        <zip>2200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Gasthuisberg</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Mouscron</name>
      <address>
        <city>Mouscron</city>
        <zip>7700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>4- MBAL</name>
      <address>
        <city>Sofia</city>
        <zip>1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL Sveti Ivan Rilski, Klinika po Gastroenterologia</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MBAL SofiaMed OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1797</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GI Research Institute (GIRI)</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2K5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Dr. David C. Pearson</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6R3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Office of Drs. Ranjit Andrew Singh and Jamie D. Papp</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PerCuro Clinical Research Limited</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8V 3P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences Corporation, McMaster University Medical Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre - University Hospital</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oshawa Clinic</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1H 1B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pavillion Rachel Tourigny, Hopital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hepato-Gastroenterology HK s.r.o.</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>50012</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinické Centrum ISCARE I.V.F</name>
      <address>
        <city>Praha 7</city>
        <zip>170 04</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krajska zdravotni, a.s., Masarykova nemocnice v Usti nad Labem o.z.</name>
      <address>
        <city>Usti nad Labem</city>
        <zip>401 13</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Amiens - Hôpital Nord</name>
      <address>
        <city>Amiens Cedex 01</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire (CHU) de Caen - Hopital Cote de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Huriez CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037 Cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital l'Archet 2 CHU de Nice</name>
      <address>
        <city>Nice Cedex 03</city>
        <zip>CS23079 06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Service de Gastro-entérologie</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Hopital Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Schleswig-Holstein, Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus GmbH</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pannonia Maganorvosi Centrum Kft</name>
      <address>
        <city>Budapest</city>
        <zip>1136</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Csongrad Megyei Dr. Bugyi Istvan Korhaz</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Institute</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology and Liver Diseases Unit - Hadassah Ein Kerem University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept. of Gastroenterology &amp; Hepatology, Meir Medical Center</name>
      <address>
        <city>Kfar-Saba</city>
        <zip>44281</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterology Division, Rabin Medical Center, Beilinson Campus</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Chaim Sheba Medical Center</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>5262000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' degli Studi &quot;Magna Graecia&quot; di Catanzaro, UO di Fisiopatologia Digestiva</name>
      <address>
        <city>Localita Germaneto</city>
        <state>Catanzaro</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IBD Center - Divisione Gastroenterologia - Istituto Clinico Humanitas IRCCS</name>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Donato</name>
      <address>
        <city>Milano</city>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera -Università di Padova</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria, Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita Cattolica Sacro Cuore Policlinico &quot;A. Gemelli&quot;</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOS San Camillo Forlanini</name>
      <address>
        <city>Rome</city>
        <zip>00152</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Casa Sollievo della Sofferenza</name>
      <address>
        <city>San Giovanni Rotondo (FG)</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yeungnam University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>705717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University College of Medicine, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center - University of Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southern Endoscopy Centre</name>
      <address>
        <city>Christchurch</city>
        <zip>8014</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Neurology &amp; EMG Ltd.</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hamilton Eye Clinic</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiac Services Ltd.</name>
      <address>
        <city>Hamilton</city>
        <zip>3216</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Waikato Hospital</name>
      <address>
        <city>Hamilton</city>
        <zip>3240</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum endoskopii Zabiegowej, Poradnia Chorob Jelitowych,</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Endoskopii Przewodu Pokarmowego</name>
      <address>
        <city>Krakow</city>
        <zip>31-009</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne - Szpital Swietej Rodziny Sp. z o.o.</name>
      <address>
        <city>Lodz</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne HCP Lecznictwo Ambulatoryjne Pracownia Endoskopowa</name>
      <address>
        <city>Poznan</city>
        <zip>61-485</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Chorob Wewnetrznych i Gastroenterologii z Pododdzialem</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Vivamed</name>
      <address>
        <city>Warszawa</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Szpital Kliniczny z Poliklinika SPOZ</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-981</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lexmedica</name>
      <address>
        <city>Wroclaw</city>
        <zip>53-114</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBEI of HPE North-West State Medical University n.a. I.I. Mechnikov of the MH of the RF St.P SBIH &quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Bezanijska Kosa, Clinic for Internal medicine</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Centre Zvezdara Clinic for Gastroenterology and Hepatology</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Military medical Academy</name>
      <address>
        <city>Belgrade</city>
        <zip>11000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital Center Zemun, Gastroenterology and Hepatology Department</name>
      <address>
        <city>Belgrade</city>
        <zip>11080</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Centre of Nis, Clinic for Gastroenterology and Hepatology</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastro I., s.r.o.</name>
      <address>
        <city>Presov</city>
        <state>Slovak Republic</state>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterological Centre Thalion</name>
      <address>
        <city>Bratislava</city>
        <zip>83104</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KM Management spol. s.r.o. Gastroenterologicke a hepatologicke centrum Nitra</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ustredna vojenska nemocnice SNP Ruzomberok</name>
      <address>
        <city>Ruzomberok</city>
        <zip>034 26</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingsbury Hospital</name>
      <address>
        <city>Claremont</city>
        <state>Cape Town</state>
        <zip>7708</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro Majadahonda</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Parc de Salut Mar-Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Teknon</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A7281009&amp;StudyName=A%20study%20Of%20PF-00547659%20In%20Patients%20With%20Moderate%20To%20Severe%20Ulcerative%20Colitis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 13, 2012</study_first_submitted>
  <study_first_submitted_qc>June 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2012</study_first_posted>
  <results_first_submitted>November 15, 2016</results_first_submitted>
  <results_first_submitted_qc>February 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 27, 2017</results_first_posted>
  <disposition_first_submitted>November 5, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>November 5, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 4, 2015</disposition_first_posted>
  <last_update_submitted>May 15, 2017</last_update_submitted>
  <last_update_submitted_qc>May 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Two (2) subjects initially randomized to the 22.5 mg group were mistakenly administered the 75 mg dose instead and were counted under that group. The numbers Started reflect the number of participants who received treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 centimeters (cm) apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="P2">
          <title>PF-00547659 7.5 mg</title>
          <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="P3">
          <title>PF-00547659 22.5 mg</title>
          <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="P4">
          <title>PF-00547659 75 mg</title>
          <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="P5">
          <title>PF-00547659 225 mg</title>
          <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="73"/>
                <participants group_id="P5" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="71"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="73"/>
                <participants group_id="P5" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="65"/>
                <participants group_id="P3" count="68"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant underwent fecal transplant</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn at discretion of investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="B2">
          <title>PF-00547659 7.5 mg</title>
          <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="B3">
          <title>PF-00547659 22.5 mg</title>
          <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="B4">
          <title>PF-00547659 75 mg</title>
          <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="B5">
          <title>PF-00547659 225 mg</title>
          <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="73"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="70"/>
            <count group_id="B4" value="73"/>
            <count group_id="B5" value="70"/>
            <count group_id="B6" value="357"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.6" spread="12.7"/>
                    <measurement group_id="B2" value="41.3" spread="12.5"/>
                    <measurement group_id="B3" value="42.1" spread="14.7"/>
                    <measurement group_id="B4" value="37.7" spread="12.4"/>
                    <measurement group_id="B5" value="41.3" spread="13.2"/>
                    <measurement group_id="B6" value="40.2" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="28"/>
                    <measurement group_id="B6" value="149"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="38"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants in Clinical Remission at Week 12</title>
        <description>Clinical remission was defined as a Total Mayo Score of less than or equal (&lt;=) 2 points with no individual subscore exceeding 1 point and rectal bleed subscore of 0 or 1. The Mayo Score is a tool designed to measure disease activity for ulcerative colitis (UC). Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
        <time_frame>Week 12</time_frame>
        <population>The primary analysis population was based on a modified intent-to-treat (mITT) analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. Two subjects initially randomized to the 22.5 mg group were mistakenly administered the 75 mg dose instead.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Clinical Remission at Week 12</title>
          <description>Clinical remission was defined as a Total Mayo Score of less than or equal (&lt;=) 2 points with no individual subscore exceeding 1 point and rectal bleed subscore of 0 or 1. The Mayo Score is a tool designed to measure disease activity for ulcerative colitis (UC). Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
          <population>The primary analysis population was based on a modified intent-to-treat (mITT) analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. Two subjects initially randomized to the 22.5 mg group were mistakenly administered the 75 mg dose instead.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Centrally read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.7" upper_limit="7.6"/>
                    <measurement group_id="O2" value="11.3" lower_limit="5.7" upper_limit="18.8"/>
                    <measurement group_id="O3" value="16.7" lower_limit="9.9" upper_limit="25.4"/>
                    <measurement group_id="O4" value="15.5" lower_limit="9.5" upper_limit="23.6"/>
                    <measurement group_id="O5" value="5.7" lower_limit="2.5" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" lower_limit="2.4" upper_limit="12.0"/>
                    <measurement group_id="O2" value="14.1" lower_limit="7.8" upper_limit="22.0"/>
                    <measurement group_id="O3" value="23.6" lower_limit="15.6" upper_limit="33.1"/>
                    <measurement group_id="O4" value="18.3" lower_limit="11.9" upper_limit="27.1"/>
                    <measurement group_id="O5" value="12.9" lower_limit="7.3" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg versus (vs) placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0213</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.080</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.019</ci_lower_limit>
            <ci_upper_limit>0.140</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0025</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.128</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.056</ci_lower_limit>
            <ci_upper_limit>0.199</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0040</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.118</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.048</ci_lower_limit>
            <ci_upper_limit>0.188</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1803</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.026</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.012</ci_lower_limit>
            <ci_upper_limit>0.064</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0582</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.080</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.002</ci_lower_limit>
            <ci_upper_limit>0.159</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0014</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.178</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.083</ci_lower_limit>
            <ci_upper_limit>0.272</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0125</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.122</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.036</ci_lower_limit>
            <ci_upper_limit>0.208</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0927</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.066</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.009</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Clinical Response at Week 12</title>
        <description>Clinical response was defined as a decrease from baseline of at least 3 points in Total Mayo Score with at least a 30 percent (%) change, accompanied by at least 1 point decrease or absolute score of 0 or 1 in rectal bleeding subscore. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
        <time_frame>Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of participants evaluable for the specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Clinical Response at Week 12</title>
          <description>Clinical response was defined as a decrease from baseline of at least 3 points in Total Mayo Score with at least a 30 percent (%) change, accompanied by at least 1 point decrease or absolute score of 0 or 1 in rectal bleeding subscore. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of participants evaluable for the specified category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Centrally read (n=73,71,72,71,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8" lower_limit="20.2" upper_limit="37.8"/>
                    <measurement group_id="O2" value="38.0" lower_limit="28.4" upper_limit="47.6"/>
                    <measurement group_id="O3" value="54.2" lower_limit="44.2" upper_limit="64.2"/>
                    <measurement group_id="O4" value="45.1" lower_limit="35.0" upper_limit="55.3"/>
                    <measurement group_id="O5" value="50.0" lower_limit="39.6" upper_limit="60.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally read (n=73,70,72,70,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9" lower_limit="24.2" upper_limit="42.3"/>
                    <measurement group_id="O2" value="38.6" lower_limit="28.8" upper_limit="48.1"/>
                    <measurement group_id="O3" value="54.2" lower_limit="44.2" upper_limit="64.2"/>
                    <measurement group_id="O4" value="48.6" lower_limit="38.2" upper_limit="59.0"/>
                    <measurement group_id="O5" value="51.4" lower_limit="41.0" upper_limit="61.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1379</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.089</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.037</ci_lower_limit>
            <ci_upper_limit>0.214</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0011</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.254</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.121</ci_lower_limit>
            <ci_upper_limit>0.388</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0239</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.163</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.032</ci_lower_limit>
            <ci_upper_limit>0.293</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0052</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.213</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.080</ci_lower_limit>
            <ci_upper_limit>0.347</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2617</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.056</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.075</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0058</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.212</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.077</ci_lower_limit>
            <ci_upper_limit>0.347</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0326</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.156</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.022</ci_lower_limit>
            <ci_upper_limit>0.290</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0145</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.185</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.320</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Mucosal Healing at Week 12</title>
        <description>Mucosal healing was defined as absolute Mayo subscore for endoscopy of 0 or 1. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
        <time_frame>Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mucosal Healing at Week 12</title>
          <description>Mucosal healing was defined as absolute Mayo subscore for endoscopy of 0 or 1. The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Centrally read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="3.6" upper_limit="15.4"/>
                    <measurement group_id="O2" value="15.5" lower_limit="9.5" upper_limit="23.6"/>
                    <measurement group_id="O3" value="27.8" lower_limit="19.5" upper_limit="37.1"/>
                    <measurement group_id="O4" value="25.4" lower_limit="17.1" upper_limit="35.0"/>
                    <measurement group_id="O5" value="14.3" lower_limit="8.0" upper_limit="22.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally read</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" lower_limit="14.9" upper_limit="31.4"/>
                    <measurement group_id="O2" value="22.5" lower_limit="15.4" upper_limit="31.6"/>
                    <measurement group_id="O3" value="37.5" lower_limit="28.0" upper_limit="47.2"/>
                    <measurement group_id="O4" value="35.2" lower_limit="25.8" upper_limit="44.7"/>
                    <measurement group_id="O5" value="28.6" lower_limit="20.2" upper_limit="38.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0618</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.081</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.000</ci_lower_limit>
            <ci_upper_limit>0.162</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.187</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.091</ci_lower_limit>
            <ci_upper_limit>0.284</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0027</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.159</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.068</ci_lower_limit>
            <ci_upper_limit>0.250</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, centrally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0999</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.069</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.013</ci_lower_limit>
            <ci_upper_limit>0.151</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5225</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.001</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.111</ci_lower_limit>
            <ci_upper_limit>0.114</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0246</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.154</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.278</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0464</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.130</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.008</ci_lower_limit>
            <ci_upper_limit>0.253</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, locally read</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2000</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.066</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.053</ci_lower_limit>
            <ci_upper_limit>0.186</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Absolute Partial Mayo Score of Less Than or Equal to (&lt;=) 2 With no Individual Subscore More Than (&gt;) 1 at Weeks 4, 8, and 12</title>
        <description>An absolute Partial Mayo Score of &lt;=2 corresponds to remission. However, this endpoint was incorrectly stated in the protocol and instead of &quot;absolute Partial Mayo Score &lt;=2&quot;, it was stated as &quot;change from baseline in Partial Mayo Score &lt;=2&quot;.</description>
        <time_frame>Weeks 4, 8, and 12</time_frame>
        <population>As this endpoint was incorrectly stated in the protocol, no analyses were done and no data are presented.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Absolute Partial Mayo Score of Less Than or Equal to (&lt;=) 2 With no Individual Subscore More Than (&gt;) 1 at Weeks 4, 8, and 12</title>
          <description>An absolute Partial Mayo Score of &lt;=2 corresponds to remission. However, this endpoint was incorrectly stated in the protocol and instead of &quot;absolute Partial Mayo Score &lt;=2&quot;, it was stated as &quot;change from baseline in Partial Mayo Score &lt;=2&quot;.</description>
          <population>As this endpoint was incorrectly stated in the protocol, no analyses were done and no data are presented.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Mayo Score at Week 12</title>
        <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants in that specified category.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Mayo Score at Week 12</title>
          <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores, each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants in that specified category.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Centrally read baseline (n=73,71,72,71,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.71"/>
                    <measurement group_id="O2" value="8.7" spread="1.65"/>
                    <measurement group_id="O3" value="8.1" spread="1.63"/>
                    <measurement group_id="O4" value="8.4" spread="1.94"/>
                    <measurement group_id="O5" value="8.7" spread="1.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Centrally read change (n=67,63,69,67,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5" spread="2.42" lower_limit="-2.043" upper_limit="-1.014"/>
                    <measurement group_id="O2" value="-2.4" spread="2.78" lower_limit="-2.944" upper_limit="-1.881"/>
                    <measurement group_id="O3" value="-2.9" spread="2.49" lower_limit="-3.570" upper_limit="-2.550"/>
                    <measurement group_id="O4" value="-2.5" spread="2.74" lower_limit="-3.162" upper_limit="-2.131"/>
                    <measurement group_id="O5" value="-2.9" spread="2.78" lower_limit="-3.337" upper_limit="-2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally read baseline (n=73,70,72,70,70)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="1.72"/>
                    <measurement group_id="O2" value="8.8" spread="1.59"/>
                    <measurement group_id="O3" value="8.1" spread="1.72"/>
                    <measurement group_id="O4" value="8.3" spread="1.99"/>
                    <measurement group_id="O5" value="8.6" spread="1.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Locally read change (n=67,62,70,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.55" lower_limit="-2.280" upper_limit="-1.171"/>
                    <measurement group_id="O2" value="-2.7" spread="3.05" lower_limit="-3.241" upper_limit="-2.084"/>
                    <measurement group_id="O3" value="-3.1" spread="2.70" lower_limit="-3.866" upper_limit="-2.775"/>
                    <measurement group_id="O4" value="-2.7" spread="2.92" lower_limit="-3.357" upper_limit="-2.236"/>
                    <measurement group_id="O5" value="-3.1" spread="3.07" lower_limit="-3.583" upper_limit="-2.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, centrally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0494</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>Least Squares Mean (LSM) Difference</param_type>
            <param_value>-0.88</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.623</ci_lower_limit>
            <ci_upper_limit>-0.145</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, centrally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.53</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.254</ci_lower_limit>
            <ci_upper_limit>-0.809</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, centrally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0117</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.845</ci_lower_limit>
            <ci_upper_limit>-0.390</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, centrally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0049</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.27</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.016</ci_lower_limit>
            <ci_upper_limit>-0.533</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, locally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0543</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.737</ci_lower_limit>
            <ci_upper_limit>-0.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, locally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.60</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.372</ci_lower_limit>
            <ci_upper_limit>-0.819</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, locally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0255</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.07</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.858</ci_lower_limit>
            <ci_upper_limit>-0.284</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, locally read change</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0079</p_value>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance (ANCOVA) with model terms: treatment group, baseline, status of anti-tumor necrosis factor (TNF) therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.082</ci_lower_limit>
            <ci_upper_limit>-0.493</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Change From Baseline in Individual Mayo Subscores - Stool Frequency, Rectal Bleeding, and Physician's Global Assessment (PGA) - at Weeks 4, 8, and 12</title>
        <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of less than (&lt;) 0, 0, and &gt;0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.</description>
        <time_frame>Baseline; Weeks (W) 4, 8, and 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at that specific time point for that endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change From Baseline in Individual Mayo Subscores - Stool Frequency, Rectal Bleeding, and Physician's Global Assessment (PGA) - at Weeks 4, 8, and 12</title>
          <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of less than (&lt;) 0, 0, and &gt;0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at that specific time point for that endpoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Imp in Stool frequency, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.87" lower_limit="-2.043" upper_limit="-1.014"/>
                    <measurement group_id="O2" value="46.88" lower_limit="-2.944" upper_limit="-1.881"/>
                    <measurement group_id="O3" value="36.62" lower_limit="-3.570" upper_limit="-2.550"/>
                    <measurement group_id="O4" value="30.43" lower_limit="-3.162" upper_limit="-2.131"/>
                    <measurement group_id="O5" value="43.08" lower_limit="-3.337" upper_limit="-2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in Stool frequency, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.70" lower_limit="-2.280" upper_limit="-1.171"/>
                    <measurement group_id="O2" value="42.19" lower_limit="-3.241" upper_limit="-2.084"/>
                    <measurement group_id="O3" value="60.56" lower_limit="-3.866" upper_limit="-2.775"/>
                    <measurement group_id="O4" value="63.77" lower_limit="-3.357" upper_limit="-2.236"/>
                    <measurement group_id="O5" value="52.31" lower_limit="-3.583" upper_limit="-2.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in Stool frequency, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.43"/>
                    <measurement group_id="O2" value="10.94"/>
                    <measurement group_id="O3" value="2.82"/>
                    <measurement group_id="O4" value="5.80"/>
                    <measurement group_id="O5" value="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in Stool frequency, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.17"/>
                    <measurement group_id="O2" value="49.21"/>
                    <measurement group_id="O3" value="43.66"/>
                    <measurement group_id="O4" value="49.28"/>
                    <measurement group_id="O5" value="51.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in Stool frequency, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.56"/>
                    <measurement group_id="O2" value="42.86"/>
                    <measurement group_id="O3" value="53.52"/>
                    <measurement group_id="O4" value="46.38"/>
                    <measurement group_id="O5" value="48.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in Stool frequency, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27"/>
                    <measurement group_id="O2" value="7.94"/>
                    <measurement group_id="O3" value="2.82"/>
                    <measurement group_id="O4" value="4.35"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in Stool frequency, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.82"/>
                    <measurement group_id="O2" value="49.21"/>
                    <measurement group_id="O3" value="56.34"/>
                    <measurement group_id="O4" value="45.59"/>
                    <measurement group_id="O5" value="56.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in Stool frequency, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.24"/>
                    <measurement group_id="O2" value="41.27"/>
                    <measurement group_id="O3" value="38.03"/>
                    <measurement group_id="O4" value="48.53"/>
                    <measurement group_id="O5" value="37.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in Stool frequency, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.94"/>
                    <measurement group_id="O2" value="9.52"/>
                    <measurement group_id="O3" value="5.63"/>
                    <measurement group_id="O4" value="5.88"/>
                    <measurement group_id="O5" value="6.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in Rectal Bleeding, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.39"/>
                    <measurement group_id="O2" value="48.44"/>
                    <measurement group_id="O3" value="42.25"/>
                    <measurement group_id="O4" value="42.03"/>
                    <measurement group_id="O5" value="49.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in Rectal Bleeding, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.69"/>
                    <measurement group_id="O2" value="42.19"/>
                    <measurement group_id="O3" value="57.75"/>
                    <measurement group_id="O4" value="53.62"/>
                    <measurement group_id="O5" value="44.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in Rectal Bleeding, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.93"/>
                    <measurement group_id="O2" value="9.38"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4.35"/>
                    <measurement group_id="O5" value="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in Rectal Bleeding, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.80"/>
                    <measurement group_id="O2" value="50.79"/>
                    <measurement group_id="O3" value="40.85"/>
                    <measurement group_id="O4" value="46.38"/>
                    <measurement group_id="O5" value="64.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in Rectal Bleeding, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.93"/>
                    <measurement group_id="O2" value="36.51"/>
                    <measurement group_id="O3" value="50.70"/>
                    <measurement group_id="O4" value="44.93"/>
                    <measurement group_id="O5" value="33.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in Rectal Bleeding, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.27"/>
                    <measurement group_id="O2" value="12.70"/>
                    <measurement group_id="O3" value="8.45"/>
                    <measurement group_id="O4" value="8.70"/>
                    <measurement group_id="O5" value="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in Rectal Bleeding, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.31"/>
                    <measurement group_id="O2" value="53.97"/>
                    <measurement group_id="O3" value="50.70"/>
                    <measurement group_id="O4" value="47.06"/>
                    <measurement group_id="O5" value="60.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in Rectal Bleeding, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.75"/>
                    <measurement group_id="O2" value="34.92"/>
                    <measurement group_id="O3" value="42.25"/>
                    <measurement group_id="O4" value="45.59"/>
                    <measurement group_id="O5" value="35.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in Rectal Bleeding, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.94"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="7.04"/>
                    <measurement group_id="O4" value="7.35"/>
                    <measurement group_id="O5" value="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in PGA, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.76"/>
                    <measurement group_id="O2" value="57.81"/>
                    <measurement group_id="O3" value="56.34"/>
                    <measurement group_id="O4" value="56.52"/>
                    <measurement group_id="O5" value="60.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in PGA, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.25"/>
                    <measurement group_id="O2" value="34.38"/>
                    <measurement group_id="O3" value="39.44"/>
                    <measurement group_id="O4" value="42.03"/>
                    <measurement group_id="O5" value="35.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in PGA, W4 (n=67,64,71,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99"/>
                    <measurement group_id="O2" value="7.81"/>
                    <measurement group_id="O3" value="4.23"/>
                    <measurement group_id="O4" value="1.45"/>
                    <measurement group_id="O5" value="4.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in PGA, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.15"/>
                    <measurement group_id="O2" value="61.90"/>
                    <measurement group_id="O3" value="66.20"/>
                    <measurement group_id="O4" value="62.32"/>
                    <measurement group_id="O5" value="67.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in PGA, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.80"/>
                    <measurement group_id="O2" value="30.16"/>
                    <measurement group_id="O3" value="30.99"/>
                    <measurement group_id="O4" value="37.68"/>
                    <measurement group_id="O5" value="30.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in PGA, W8 (n=71,63,71,69,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.04"/>
                    <measurement group_id="O2" value="7.94"/>
                    <measurement group_id="O3" value="2.82"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Imp in PGA, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.75"/>
                    <measurement group_id="O2" value="61.90"/>
                    <measurement group_id="O3" value="64.79"/>
                    <measurement group_id="O4" value="55.88"/>
                    <measurement group_id="O5" value="57.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC in PGA, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.28"/>
                    <measurement group_id="O2" value="31.75"/>
                    <measurement group_id="O3" value="32.39"/>
                    <measurement group_id="O4" value="39.71"/>
                    <measurement group_id="O5" value="32.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors in PGA, W12 (n=67,63,71,68,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.97"/>
                    <measurement group_id="O2" value="6.35"/>
                    <measurement group_id="O3" value="2.82"/>
                    <measurement group_id="O4" value="4.41"/>
                    <measurement group_id="O5" value="9.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Stool Frequency, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1016</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Linear Mixed Model (LMM) with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.511</ci_lower_limit>
            <ci_upper_limit>0.001</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Stool Frequency, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0654</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.529</ci_lower_limit>
            <ci_upper_limit>-0.030</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Stool Frequency, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1500</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.472</ci_lower_limit>
            <ci_upper_limit>0.031</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Stool Frequency, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0132</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.38</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.637</ci_lower_limit>
            <ci_upper_limit>-0.129</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Stool Frequency, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0526</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.555</ci_lower_limit>
            <ci_upper_limit>-0.046</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Stool Frequency, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0422</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.554</ci_lower_limit>
            <ci_upper_limit>-0.058</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Stool Frequency, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0110</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.637</ci_lower_limit>
            <ci_upper_limit>-0.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Stool Frequency, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.755</ci_lower_limit>
            <ci_upper_limit>-0.254</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Stool Frequency, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1611</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.475</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Stool Frequency, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0186</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.36</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.608</ci_lower_limit>
            <ci_upper_limit>-0.108</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Stool Frequency, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1647</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.465</ci_lower_limit>
            <ci_upper_limit>0.039</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Stool Frequency, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0231</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.35</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.607</ci_lower_limit>
            <ci_upper_limit>-0.097</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Rectal Bleeding, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.46</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.658</ci_lower_limit>
            <ci_upper_limit>-0.260</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Rectal Bleeding, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.52</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.710</ci_lower_limit>
            <ci_upper_limit>-0.322</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Rectal Bleeding, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.49</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.686</ci_lower_limit>
            <ci_upper_limit>-0.295</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Rectal Bleeding, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.587</ci_lower_limit>
            <ci_upper_limit>-0.192</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Rectal Bleeding, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0207</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.28</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.475</ci_lower_limit>
            <ci_upper_limit>-0.081</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Rectal Bleeding, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0402</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.432</ci_lower_limit>
            <ci_upper_limit>-0.048</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Rectal Bleeding, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0071</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.511</ci_lower_limit>
            <ci_upper_limit>-0.124</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Rectal Bleeding, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.664</ci_lower_limit>
            <ci_upper_limit>-0.275</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Rectal Bleeding, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0395</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.449</ci_lower_limit>
            <ci_upper_limit>-0.050</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Rectal Bleeding, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.511</ci_lower_limit>
            <ci_upper_limit>-0.123</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Rectal Bleeding, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0413</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.439</ci_lower_limit>
            <ci_upper_limit>-0.047</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Rectal Bleeding, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0008</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.40</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.602</ci_lower_limit>
            <ci_upper_limit>-0.206</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, PGA, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1862</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.421</ci_lower_limit>
            <ci_upper_limit>0.046</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, PGA, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0998</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.455</ci_lower_limit>
            <ci_upper_limit>-0.000</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, PGA, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1085</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.453</ci_lower_limit>
            <ci_upper_limit>0.006</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, PGA, W4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3161</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.372</ci_lower_limit>
            <ci_upper_limit>0.090</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, PGA, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4962</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.328</ci_lower_limit>
            <ci_upper_limit>0.136</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, PGA, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0371</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.29</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.512</ci_lower_limit>
            <ci_upper_limit>-0.060</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, PGA, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1212</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.21</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.441</ci_lower_limit>
            <ci_upper_limit>0.013</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, PGA, W8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1870</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.18</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.410</ci_lower_limit>
            <ci_upper_limit>0.045</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, PGA, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1133</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.459</ci_lower_limit>
            <ci_upper_limit>0.009</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, PGA, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0022</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.653</ci_lower_limit>
            <ci_upper_limit>-0.198</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, PGA, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0788</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.475</ci_lower_limit>
            <ci_upper_limit>-0.016</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, PGA, W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0717</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.25</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.485</ci_lower_limit>
            <ci_upper_limit>-0.022</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Change From Baseline in Individual Mayo Subscore - Findings on Flexible Sigmoidoscopy - at Week 12</title>
        <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of &lt;0, 0, and &gt;0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Change From Baseline in Individual Mayo Subscore - Findings on Flexible Sigmoidoscopy - at Week 12</title>
          <description>The Mayo Score is a tool designed to measure disease activity for UC. Scoring ranges from 0 to 12 points and consists of 4 subscores (stool frequency, rectal bleeding, PGA, findings on flexible sigmoidoscopy), each graded 0 to 3 with higher score indicating more severe disease activity. Endoscopic readings from the local and the central reader were considered for analysis. The central reading was used as the primary analysis and the local readings were used for the sensitivity analyses. Changes from baseline in the subscore of &lt;0, 0, and &gt;0 corresponded to improvement (imp), no change (NC), and worsening (wors) in that specific subscore.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at Week 12.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Imp (n=67,63,69,67,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.37" lower_limit="-2.043" upper_limit="-1.014"/>
                    <measurement group_id="O2" value="28.57" lower_limit="-2.944" upper_limit="-1.881"/>
                    <measurement group_id="O3" value="47.83" lower_limit="-3.570" upper_limit="-2.550"/>
                    <measurement group_id="O4" value="47.76" lower_limit="-3.162" upper_limit="-2.131"/>
                    <measurement group_id="O5" value="39.68" lower_limit="-3.337" upper_limit="-2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NC (n=67,63,69,67,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.19" lower_limit="-2.280" upper_limit="-1.171"/>
                    <measurement group_id="O2" value="60.32" lower_limit="-3.241" upper_limit="-2.084"/>
                    <measurement group_id="O3" value="49.28" lower_limit="-3.866" upper_limit="-2.775"/>
                    <measurement group_id="O4" value="46.27" lower_limit="-3.357" upper_limit="-2.236"/>
                    <measurement group_id="O5" value="57.14" lower_limit="-3.583" upper_limit="-2.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wors (n=67,63,69,67,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.43"/>
                    <measurement group_id="O2" value="11.11"/>
                    <measurement group_id="O3" value="2.90"/>
                    <measurement group_id="O4" value="5.97"/>
                    <measurement group_id="O5" value="3.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5406</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.286</ci_lower_limit>
            <ci_upper_limit>0.131</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.628</ci_lower_limit>
            <ci_upper_limit>-0.221</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0063</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.34</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.549</ci_lower_limit>
            <ci_upper_limit>-0.137</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0748</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA with model terms: treatment group, baseline, status of anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.436</ci_lower_limit>
            <ci_upper_limit>-0.018</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in Fecal Calprotectin at Weeks 4, 8, and 12</title>
        <description>Fecal calprotectin was one of the pharmacodynamic (PD) biomarkers of the study.</description>
        <time_frame>Baseline, Weeks 4, 8, and 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at that specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in Fecal Calprotectin at Weeks 4, 8, and 12</title>
          <description>Fecal calprotectin was one of the pharmacodynamic (PD) biomarkers of the study.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at that specific time point.</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=62,57,68,67,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.62" lower_limit="-43.49" upper_limit="-2.09"/>
                    <measurement group_id="O2" value="-40.21" lower_limit="-55.56" upper_limit="-19.54"/>
                    <measurement group_id="O3" value="-23.50" lower_limit="-44.27" upper_limit="5.00"/>
                    <measurement group_id="O4" value="-46.22" lower_limit="-61.46" upper_limit="-24.95"/>
                    <measurement group_id="O5" value="-39.27" lower_limit="-56.74" upper_limit="-14.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=67,57,67,63,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.68" lower_limit="-39.62" upper_limit="1.60"/>
                    <measurement group_id="O2" value="-44.49" lower_limit="-60.05" upper_limit="-22.88"/>
                    <measurement group_id="O3" value="-44.77" lower_limit="-60.49" upper_limit="-22.80"/>
                    <measurement group_id="O4" value="-57.20" lower_limit="-69.74" upper_limit="-39.45"/>
                    <measurement group_id="O5" value="-49.54" lower_limit="-65.08" upper_limit="-27.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=61,55,64,64,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.59" lower_limit="-42.68" upper_limit="4.54"/>
                    <measurement group_id="O2" value="-56.34" lower_limit="-69.39" upper_limit="-37.72"/>
                    <measurement group_id="O3" value="-58.41" lower_limit="-72.26" upper_limit="-37.65"/>
                    <measurement group_id="O4" value="-56.72" lower_limit="-71.67" upper_limit="-33.88"/>
                    <measurement group_id="O5" value="-64.52" lower_limit="-76.92" upper_limit="-45.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9744</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-101.00</ci_lower_limit>
            <ci_upper_limit>97.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2023</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>74.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-21.77</ci_lower_limit>
            <ci_upper_limit>171.66</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5808</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>32.9</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-65.09</ci_lower_limit>
            <ci_upper_limit>130.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5388</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>37.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-63.12</ci_lower_limit>
            <ci_upper_limit>138.34</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8902</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-8.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-106.24</ci_lower_limit>
            <ci_upper_limit>89.81</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8616</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>10.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-86.14</ci_lower_limit>
            <ci_upper_limit>106.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5684</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-34.3</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-133.49</ci_lower_limit>
            <ci_upper_limit>64.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5700</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>33.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.20</ci_lower_limit>
            <ci_upper_limit>131.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6234</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-30.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-130.56</ci_lower_limit>
            <ci_upper_limit>70.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5474</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>36.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.44</ci_lower_limit>
            <ci_upper_limit>134.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo,Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1918</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>78.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.48</ci_lower_limit>
            <ci_upper_limit>177.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9615</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-3.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-104.88</ci_lower_limit>
            <ci_upper_limit>98.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 4, 8, and 12</title>
        <description>hsCRP was one of the PD biomarkers of the study.</description>
        <time_frame>Baseline; Weeks 4, 8, and 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at that specific time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline in High Sensitivity C-reactive Protein (hsCRP) at Weeks 4, 8, and 12</title>
          <description>hsCRP was one of the PD biomarkers of the study.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at that specific time point.</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=67,64,69,71,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.60" lower_limit="-25.69" upper_limit="5.17"/>
                    <measurement group_id="O2" value="-19.17" lower_limit="-34.22" upper_limit="-0.67"/>
                    <measurement group_id="O3" value="-26.90" lower_limit="-39.41" upper_limit="-11.82"/>
                    <measurement group_id="O4" value="-35.21" lower_limit="-49.10" upper_limit="-17.55"/>
                    <measurement group_id="O5" value="-17.70" lower_limit="-30.08" upper_limit="-3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=71,63,69,71,68)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.42" lower_limit="-22.75" upper_limit="23.25"/>
                    <measurement group_id="O2" value="-6.00" lower_limit="-23.09" upper_limit="14.89"/>
                    <measurement group_id="O3" value="-31.43" lower_limit="-44.11" upper_limit="-15.88"/>
                    <measurement group_id="O4" value="-43.15" lower_limit="-54.57" upper_limit="-28.86"/>
                    <measurement group_id="O5" value="-22.70" lower_limit="-36.72" upper_limit="-5.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=67,62,68,71,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.85" lower_limit="-11.16" upper_limit="48.48"/>
                    <measurement group_id="O2" value="4.51" lower_limit="-18.02" upper_limit="33.25"/>
                    <measurement group_id="O3" value="-20.40" lower_limit="-38.61" upper_limit="3.22"/>
                    <measurement group_id="O4" value="-15.96" lower_limit="-33.12" upper_limit="5.60"/>
                    <measurement group_id="O5" value="2.31" lower_limit="-18.48" upper_limit="28.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9328</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>6.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-118.60</ci_lower_limit>
            <ci_upper_limit>131.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8962</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-9.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-132.91</ci_lower_limit>
            <ci_upper_limit>113.39</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8775</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>11.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-110.83</ci_lower_limit>
            <ci_upper_limit>133.74</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Week 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8224</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-17.0</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-142.02</ci_lower_limit>
            <ci_upper_limit>107.94</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4831</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-52.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-176.48</ci_lower_limit>
            <ci_upper_limit>71.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1183</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-115.2</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-236.63</ci_lower_limit>
            <ci_upper_limit>6.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1139</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-115.8</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-236.29</ci_lower_limit>
            <ci_upper_limit>4.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Week 8</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1931</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-96.4</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-218.17</ci_lower_limit>
            <ci_upper_limit>25.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1182</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-119.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-245.66</ci_lower_limit>
            <ci_upper_limit>6.32</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5784</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-41.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-165.34</ci_lower_limit>
            <ci_upper_limit>81.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo,Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0279</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-163.6</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-285.84</ci_lower_limit>
            <ci_upper_limit>-41.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, Week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1053</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-123.5</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-249.00</ci_lower_limit>
            <ci_upper_limit>1.93</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12</title>
        <description>IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score at Week 12</title>
          <description>IBDQ: Psychometrically validated patient reported outcome (PRO) instrument for measuring disease-specific quality of life (QOL) in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at the specified time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (BL)(n=69,68,65,71,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.0" spread="30.69" lower_limit="-2.043" upper_limit="-1.014"/>
                    <measurement group_id="O2" value="122.1" spread="38.82" lower_limit="-2.944" upper_limit="-1.881"/>
                    <measurement group_id="O3" value="133.4" spread="34.79" lower_limit="-3.570" upper_limit="-2.550"/>
                    <measurement group_id="O4" value="128.0" spread="32.42" lower_limit="-3.162" upper_limit="-2.131"/>
                    <measurement group_id="O5" value="132.3" spread="36.84" lower_limit="-3.337" upper_limit="-2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at W12 (n=62,55,61,64,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="34.08" lower_limit="-2.280" upper_limit="-1.171"/>
                    <measurement group_id="O2" value="20.1" spread="35.24" lower_limit="-3.241" upper_limit="-2.084"/>
                    <measurement group_id="O3" value="32.7" spread="34.10" lower_limit="-3.866" upper_limit="-2.775"/>
                    <measurement group_id="O4" value="32.1" spread="31.70" lower_limit="-3.357" upper_limit="-2.236"/>
                    <measurement group_id="O5" value="36.2" spread="29.45" lower_limit="-3.583" upper_limit="-2.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8302</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-1.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.507</ci_lower_limit>
            <ci_upper_limit>7.317</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0141</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>12.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.084</ci_lower_limit>
            <ci_upper_limit>20.567</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0182</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>11.70</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.564</ci_lower_limit>
            <ci_upper_limit>19.840</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0026</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>15.48</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.056</ci_lower_limit>
            <ci_upper_limit>23.907</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Scores at Week 12</title>
        <description>IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. There are 4 individual domains under the IBDQ: bowel function (fx)/symptoms (score range of 10-70), systemic symptoms (score range of 5-35), emotional status/fx (score range of 12-84), and social fx (score range of 5-35). As with total score, higher scores indicate better QOL in that domain.</description>
        <time_frame>Baseline (BL), Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at the specified time point for that specific domain.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inflammatory Bowel Disease Questionnaire (IBDQ) Domain Scores at Week 12</title>
          <description>IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is the sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. There are 4 individual domains under the IBDQ: bowel function (fx)/symptoms (score range of 10-70), systemic symptoms (score range of 5-35), emotional status/fx (score range of 12-84), and social fx (score range of 5-35). As with total score, higher scores indicate better QOL in that domain.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment. n=number of evaluable participants at the specified time point for that specific domain.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BL, bowel fx (n=69,68,65,71,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="9.96" lower_limit="-2.043" upper_limit="-1.014"/>
                    <measurement group_id="O2" value="37.0" spread="12.23" lower_limit="-2.944" upper_limit="-1.881"/>
                    <measurement group_id="O3" value="41.7" spread="10.60" lower_limit="-3.570" upper_limit="-2.550"/>
                    <measurement group_id="O4" value="38.5" spread="9.95" lower_limit="-3.162" upper_limit="-2.131"/>
                    <measurement group_id="O5" value="41.0" spread="11.37" lower_limit="-3.337" upper_limit="-2.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at W12, bowel fx (n=62,55,61,64,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="11.93" lower_limit="-2.280" upper_limit="-1.171"/>
                    <measurement group_id="O2" value="6.9" spread="12.51" lower_limit="-3.241" upper_limit="-2.084"/>
                    <measurement group_id="O3" value="11.3" spread="11.05" lower_limit="-3.866" upper_limit="-2.775"/>
                    <measurement group_id="O4" value="11.8" spread="12.07" lower_limit="-3.357" upper_limit="-2.236"/>
                    <measurement group_id="O5" value="12.8" spread="11.45" lower_limit="-3.583" upper_limit="-2.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, emotional fx (n=69,68,65,71,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.4" spread="12.60"/>
                    <measurement group_id="O2" value="48.4" spread="15.39"/>
                    <measurement group_id="O3" value="51.2" spread="14.70"/>
                    <measurement group_id="O4" value="50.4" spread="13.73"/>
                    <measurement group_id="O5" value="51.3" spread="15.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at W12, emotional fx (n=62,55,61,64,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.9" spread="11.91"/>
                    <measurement group_id="O2" value="6.6" spread="12.22"/>
                    <measurement group_id="O3" value="10.8" spread="13.85"/>
                    <measurement group_id="O4" value="10.0" spread="12.04"/>
                    <measurement group_id="O5" value="12.0" spread="11.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, systemic symptoms (SS)(n=69,68,65,71,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.1" spread="5.62"/>
                    <measurement group_id="O2" value="18.2" spread="6.81"/>
                    <measurement group_id="O3" value="19.6" spread="5.98"/>
                    <measurement group_id="O4" value="18.4" spread="6.42"/>
                    <measurement group_id="O5" value="19.0" spread="5.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at W12, SS (n=62,55,61,64,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="6.67"/>
                    <measurement group_id="O2" value="3.1" spread="5.95"/>
                    <measurement group_id="O3" value="4.7" spread="5.91"/>
                    <measurement group_id="O4" value="4.9" spread="5.49"/>
                    <measurement group_id="O5" value="4.8" spread="5.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BL, social fx (n=69,68,65,71,66)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.6" spread="7.87"/>
                    <measurement group_id="O2" value="18.5" spread="8.07"/>
                    <measurement group_id="O3" value="20.9" spread="7.37"/>
                    <measurement group_id="O4" value="20.7" spread="6.99"/>
                    <measurement group_id="O5" value="20.9" spread="7.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at W12, social fx (n=62,55,61,64,54)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="6.27"/>
                    <measurement group_id="O2" value="3.6" spread="7.33"/>
                    <measurement group_id="O3" value="5.9" spread="6.51"/>
                    <measurement group_id="O4" value="5.4" spread="6.90"/>
                    <measurement group_id="O5" value="6.6" spread="6.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, bowel fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6862</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.73</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.689</ci_lower_limit>
            <ci_upper_limit>2.235</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, bowel fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0135</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>4.37</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.467</ci_lower_limit>
            <ci_upper_limit>7.280</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, bowel fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0171</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>4.16</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.293</ci_lower_limit>
            <ci_upper_limit>7.023</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, bowel fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0041</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>5.20</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.232</ci_lower_limit>
            <ci_upper_limit>8.172</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, emotional fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9072</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>0.22</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.897</ci_lower_limit>
            <ci_upper_limit>3.339</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, emotional fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0161</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>4.47</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.420</ci_lower_limit>
            <ci_upper_limit>7.522</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, emotional fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0271</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>4.06</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.042</ci_lower_limit>
            <ci_upper_limit>7.071</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, emotional fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0020</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>5.90</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.778</ci_lower_limit>
            <ci_upper_limit>9.026</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, systemic symptoms change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7711</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.26</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.756</ci_lower_limit>
            <ci_upper_limit>1.229</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, systemic symptoms change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0582</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>1.69</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.223</ci_lower_limit>
            <ci_upper_limit>3.147</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, systemic symptoms change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0558</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>1.68</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.235</ci_lower_limit>
            <ci_upper_limit>3.120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, systemic symptoms change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0686</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>1.66</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.161</ci_lower_limit>
            <ci_upper_limit>3.153</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo, social fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7561</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>-0.33</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.094</ci_lower_limit>
            <ci_upper_limit>1.429</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo, social fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0384</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>2.17</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.447</ci_lower_limit>
            <ci_upper_limit>3.891</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo, social fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0729</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>1.86</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.154</ci_lower_limit>
            <ci_upper_limit>3.557</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo, social fx change from BL at W12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0060</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>LMM with model terms: treatment group, time, baseline, time by treatment, status of previous anti-TNF therapy experience.</method_desc>
            <param_type>LSM Difference</param_type>
            <param_value>2.95</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.190</ci_lower_limit>
            <ci_upper_limit>4.715</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With an Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score of More Than or Equal to (&gt;=) 170 at Week 12</title>
        <description>IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. A score of &gt;=170 corresponds to clinical remission.</description>
        <time_frame>Week 12</time_frame>
        <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With an Inflammatory Bowel Disease Questionnaire (IBDQ) Total Score of More Than or Equal to (&gt;=) 170 at Week 12</title>
          <description>IBDQ: Psychometrically validated PRO instrument for measuring disease-specific QOL in participants with inflammatory bowel disease. IBDQ consists of 32 items, each item score ranged from 1 (worst possible response) to 7 (best possible response). Total score is sum of each item score, ranged from 32 to 224 with higher score indicating better QOL. Positive change in total score indicated improvement in QOL. A score of &gt;=170 corresponds to clinical remission.</description>
          <population>The primary analysis population was based on an mITT analysis set, which was defined as all randomized participants who received at least 1 dose of randomized treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="64"/>
                <count group_id="O5" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.9" lower_limit="27.4" upper_limit="47.5"/>
                    <measurement group_id="O2" value="36.8" lower_limit="26.9" upper_limit="47.9"/>
                    <measurement group_id="O3" value="55.6" lower_limit="45.0" upper_limit="66.3"/>
                    <measurement group_id="O4" value="46.9" lower_limit="36.1" upper_limit="57.5"/>
                    <measurement group_id="O5" value="48.1" lower_limit="36.3" upper_limit="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 7.5 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5201</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.002</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.145</ci_lower_limit>
            <ci_upper_limit>0.142</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 22.5 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0217</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.183</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.039</ci_lower_limit>
            <ci_upper_limit>0.328</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 75 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1473</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.096</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.045</ci_lower_limit>
            <ci_upper_limit>0.237</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>PF-00547659 225 mg vs placebo</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1231</p_value>
            <p_value_desc>1-sided p-value</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.112</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.038</ci_lower_limit>
            <ci_upper_limit>0.261</ci_upper_limit>
            <estimate_desc>Statistics of risk difference are calculated using the Minimum Risk Weights test.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs During the Treatment Period (Weeks 0-12)</title>
        <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
        <time_frame>Screening through to end of treatment period, up to 12 weeks</time_frame>
        <population>All randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Withdrawals Due to TEAEs During the Treatment Period (Weeks 0-12)</title>
          <description>An adverse event (AE) was any untoward medical occurrence attributed to study drug in a participant who received study drug. TEAEs are defined as newly occurring AEs or those worsening after first dose. AEs comprised both SAEs and non-SAEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
          <population>All randomized participants who received at least 1 dose of study treatment.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="71"/>
                <count group_id="O3" value="70"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>With SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrawals due to TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Serum PF-00547659 Concentration Achieved</title>
        <time_frame>Weeks 0 (baseline), 2, 4,8, 12, 16, 20, 24, 28, 32, and 36; Early Withdrawal</time_frame>
        <population>Participants who received active treatment (PF-00547659) were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O2">
            <title>PF-00547659 7.5 mg</title>
            <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O3">
            <title>PF-00547659 22.5 mg</title>
            <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O4">
            <title>PF-00547659 75 mg</title>
            <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
          <group group_id="O5">
            <title>PF-00547659 225 mg</title>
            <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Serum PF-00547659 Concentration Achieved</title>
          <population>Participants who received active treatment (PF-00547659) were included in this analysis.</population>
          <units>nanograms (ng)/milliliter (mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="68"/>
                <count group_id="O5" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="929.4" spread="1977.8"/>
                    <measurement group_id="O3" value="2062" spread="1395.5"/>
                    <measurement group_id="O4" value="6576" spread="2146.0"/>
                    <measurement group_id="O5" value="21470" spread="4788.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Screening till Week 36 or Early Withdrawal, whichever was later.</time_frame>
      <desc>Two subjects initially randomized to the 22.5 mg group were mistakenly administered the 75 mg dose instead.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Participants received placebo in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered placebo SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="E2">
          <title>PF-00547659 7.5 mg</title>
          <description>Participants received PF-00547659 7.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 7.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="E3">
          <title>PF-00547659 22.5 mg</title>
          <description>Participants received PF-00547659 22.5 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 22.5 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="E4">
          <title>PF-00547659 75 mg</title>
          <description>Participants received PF-00547659 75 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 75 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
        <group group_id="E5">
          <title>PF-00547659 225 mg</title>
          <description>Participants received PF-00547659 225 milligrams (mg) in the form of 3 subcutaneous (SC) injections on Days 1, 28, and 56, following the completion of most study procedures. Participants were administered PF-00547659 225 mg SC in the anterolateral right or left thighs. Injections were administered at least 3 cm apart to the same thigh beginning from the outermost section of the thigh OR 2 injections in 1 thigh about 3 cm apart and 1 in the other thigh.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Clostridium difficile infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Colectomy total</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA v18.1</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="71"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc</organization>
      <phone>18007181021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

